Anti-Diabetic Therapies and Cancer: From Bench to Bedside DOI Creative Commons
Dimitris Kounatidis, Natalia G. Vallianou, Ιrene Karampela

et al.

Biomolecules, Journal Year: 2024, Volume and Issue: 14(11), P. 1479 - 1479

Published: Nov. 20, 2024

Diabetes mellitus (DM) is a significant risk factor for various cancers, with the impact of anti-diabetic therapies on cancer progression differing across malignancies. Among these therapies, metformin has gained attention its potential anti-cancer effects, primarily through modulation AMP-activated protein kinase/mammalian target rapamycin (AMPK/mTOR) pathway and induction autophagy. Beyond metformin, other conventional treatments, such as insulin, sulfonylureas (SUs), pioglitazone, dipeptidyl peptidase-4 (DPP-4) inhibitors, have also been examined their roles in biology, though findings are often inconclusive. More recently, novel medications, like glucagon-like peptide-1 (GLP-1) receptor agonists, dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) sodium-glucose co-transporter-2 (SGLT-2) revolutionized DM management by not only improving glycemic control but delivering substantial cardiovascular renal benefits. Given diverse metabolic including anti-obesogenic properties, agents now under meticulous investigation influence tumorigenesis advancement. This review aims to offer comprehensive exploration evolving landscape glucose-lowering treatments implications biology. It critically evaluates experimental evidence surrounding molecular mechanisms which medications may modulate oncogenic signaling pathways reshape tumor microenvironment (TME). Furthermore, it assesses translational research clinical trials gauge practical relevance real-world settings. Finally, explores adjuncts treatment, particularly enhancing efficacy chemotherapy, minimizing toxicity, addressing resistance within framework immunotherapy.

Language: Английский

Lipid metabolic reprograming: the unsung hero in breast cancer progression and tumor microenvironment DOI Creative Commons
Mengting Wan,

Shuaikang Pan,

Benjie Shan

et al.

Molecular Cancer, Journal Year: 2025, Volume and Issue: 24(1)

Published: March 3, 2025

Aberrant lipid metabolism is a well-recognized hallmark of cancer. Notably, breast cancer (BC) arises from lipid-rich microenvironment and depends significantly on metabolic reprogramming to fulfill its developmental requirements. In this review, we revisit the pivotal role in BC, underscoring impact progression tumor microenvironment. Firstly, delineate overall landscape highlighting roles patient prognosis. Given that lipids can also act as signaling molecules, next describe exchanges between BC cells other cellular components Additionally, summarize therapeutic potential targeting aspects processes, lipid-related transcription factors immunotherapy BC. Finally, discuss possibilities problems associated with clinical applications lipid‑targeted therapy propose new research directions advances spatiotemporal multi-omics.

Language: Английский

Citations

0
Therapeutic Potential and Challenges of Pioglitazone in Cancer Treatment DOI Creative Commons
Maria Vasileiou, Sotirios Charalampos Diamantoudis, Christina Tsianava

et al.

Applied Sciences, Journal Year: 2025, Volume and Issue: 15(4), P. 1925 - 1925

Published: Feb. 13, 2025

Pioglitazone (ACTOS) is a thiazolidinedione for peroxisome proliferator-activated receptor γ (PPAR-γ) that has been well established the second or third line treatment of type 2 diabetes mellitus. Beyond effects on glucose metabolism, pioglitazone displays positive lipid blood pressure, endothelial function, bone density, and apoptosis cancer cells. In fact, according to in vitro experiments preclinical studies, PPAR-γ ligand currently considered potential target both chemoprevention therapy. ligands are known inhibit cell proliferation metastasis through terminal differentiation underexpression inflammatory mediators. Despite its anticancer properties, was withdrawn by national medicine agencies France Germany, due reports increased incidence bladder cancer. These were associated with European populations undergoing higher doses longer durations treatment. this review, we discuss pharmacokinetics, therapeutic potential, limitations regarding clinical use pioglitazone, focus

Language: Английский

Citations

0
Harnessing Drug Repurposing to Combat Breast Cancer by Targeting Altered Metabolism and Epithelial-to-Mesenchymal Transition Pathways DOI Creative Commons

Thirukumaran Kandasamy,

Shilpi Sarkar, Siddhartha Sankar Ghosh

et al.

ACS Pharmacology & Translational Science, Journal Year: 2024, Volume and Issue: 7(12), P. 3780 - 3794

Published: Oct. 31, 2024

Breast cancer remains one of the most prevalent and challenging cancers to treat due its complexity heterogenicity. Cellular processes such as metabolic reprogramming epithelial-to-mesenchymal transition (EMT) contribute breast by driving uncontrolled cell division, metastasis, resistance therapies. Strategically targeting these intricate pathways can effectively impede progression, thereby revealing significant potential for therapeutic interventions. Among various emerging approaches, drug repurposing offers a promising avenue enhancing clinical outcomes. In recent years, high-throughput screening, QSAR, network pharmacology have been widely employed identify repurposed drugs. As an outcome, several drugs, Metformin, Itraconazole, Pimozide, Disulfiram, were regulate EMT pathways. Moreover, strategies combination therapy, targeted delivery, personalized medicine utilized enhance efficacy specificity This review focuses on altered metabolism in through repurposing. It also highlights advancements screening techniques, associated limitations, overcome challenges.

Language: Английский

Citations

0
Anti-Diabetic Therapies and Cancer: From Bench to Bedside DOI Creative Commons
Dimitris Kounatidis, Natalia G. Vallianou, Ιrene Karampela

et al.

Biomolecules, Journal Year: 2024, Volume and Issue: 14(11), P. 1479 - 1479

Published: Nov. 20, 2024

Diabetes mellitus (DM) is a significant risk factor for various cancers, with the impact of anti-diabetic therapies on cancer progression differing across malignancies. Among these therapies, metformin has gained attention its potential anti-cancer effects, primarily through modulation AMP-activated protein kinase/mammalian target rapamycin (AMPK/mTOR) pathway and induction autophagy. Beyond metformin, other conventional treatments, such as insulin, sulfonylureas (SUs), pioglitazone, dipeptidyl peptidase-4 (DPP-4) inhibitors, have also been examined their roles in biology, though findings are often inconclusive. More recently, novel medications, like glucagon-like peptide-1 (GLP-1) receptor agonists, dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) sodium-glucose co-transporter-2 (SGLT-2) revolutionized DM management by not only improving glycemic control but delivering substantial cardiovascular renal benefits. Given diverse metabolic including anti-obesogenic properties, agents now under meticulous investigation influence tumorigenesis advancement. This review aims to offer comprehensive exploration evolving landscape glucose-lowering treatments implications biology. It critically evaluates experimental evidence surrounding molecular mechanisms which medications may modulate oncogenic signaling pathways reshape tumor microenvironment (TME). Furthermore, it assesses translational research clinical trials gauge practical relevance real-world settings. Finally, explores adjuncts treatment, particularly enhancing efficacy chemotherapy, minimizing toxicity, addressing resistance within framework immunotherapy.

Language: Английский

Citations

0